Italia markets close in 3 hours 4 minutes

Cellectar Biosciences, Inc. (CLRB)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
3,6350-0,2150 (-5,58%)
Alla chiusura: 04:00PM EDT
3,8300 +0,19 (+5,36%)
Preborsa: 09:25AM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente3,8500
Aperto3,8300
Denaro3,6000 x 200
Lettera3,6900 x 500
Min-Max giorno3,5300 - 3,8800
Intervallo di 52 settimane1,3000 - 4,4500
Volume1.475.494
Media Volume1.861.552
Capitalizzazione44,668M
Beta (5 anni mensile)0,93
Rapporto PE (ttm)N/D
EPS (ttm)-3,2600
Prossima data utili02 mag 2024 - 06 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A12,60
  • GlobeNewswire

    Cellectar Biosciences Expands Global Intellectual Property Portfolio with Four Patent Grants

    FLORHAM PARK, N.J., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced significant advancements to its global intellectual property (IP) portfolio. Cellectar has secured four patents across the key global regions Europe, Australia and Canada, covering the company’s proprietary Phospholipid Drug Conjug

  • GlobeNewswire

    Cellectar Biosciences Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom’s Macroglobulinemia

    The EMA’s PRIME status is granted to drug candidates that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment optionsFLORHAM PARK, N.J., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced that the European Medicines Agency (EMA) has granted Priority

  • GlobeNewswire

    Cellectar Biosciences Announces up to Approximately $103 Million Private Placement Financing

    Transaction led by existing investor Rosalind with participation from other new and existing healthcare-focused institutional investors Pivotal topline data in Waldenstrom’s macroglobulinemia expected in Q4 2023 with NDA submission and potential product launch in 2024 FLORHAM PARK, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for th